Table 4 Mean plasma clearance and Cmax BGC9331

From: A phase I pharmacokinetic and pharmacodynamic study of BGC9331 and carboplatin in relapsed gynaecological malignancies

 

Dose level 1

Dose level 1

Dose level 2

Dose level 2

 

Day 1

Day 8

Day 1

Day 8

Median plasma clearance (ml h−1)

478±61

971±265

1197±580

746±584

Median Cmax (μg ml−1)

11.2±2.5

7.3±5.0

16.5±2.4

10.4±4.0

  1. Median plasma clearance in ml h−1±s.d. following day 1 and day 8 BGC9331 dosing at the first two dose levels in the study. The day 8 clearance at dose level 1 appears higher than that might be expected, and is not demonstrated at dose level 2. The Cmax at dose level 2 is higher than that observed at dose level 1.
Back to article page